Serlopitant

Drug Profile

Serlopitant

Alternative Names: L-1178953; MK-0594; VPD-737

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Epidermolysis Bullosa Research Partnership; Menlo Therapeutics; Merck & Co; Stanford University; Velocity Pharmaceutical Development
  • Class Cyclopentanes; Isoindoles; Small molecules; Urologics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prurigo nodularis; Pruritus
  • Discontinued Alcoholism; Overactive bladder

Most Recent Events

  • 01 Dec 2016 Tigercat Pharma is now called Menlo Therapeutics
  • 01 Nov 2016 Menlo Therapeutics initiates the phase II ATOMIK trial for Pruritus (In adolescents, In adults) in USA (PO, Tablet) (NCT02975206)
  • 01 Nov 2016 Menlo Therapeutics initiates the phase II AUBURN trial for Pruritus (In adults) in USA (PO, Tablet) (NCT02975271)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top